WHO ICTRP trial
A Study to Evaluate the Efficacy and Safety of Lenvatinib Plus Nivolumab and…
KCT0010902 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0010902 |
|---|---|
| Public title | A Study to Evaluate the Efficacy and Safety of Lenvatinib Plus Nivolumab and Chemotherapy in Metastatic Gastric Cancer with Ascites |
| Scientific title | A phase Ib/II trial of first-line lenvatinib in combination with nivolumab plus chemotherapy in metastatic gastric cancer patients with malignant ascites |
| Primary sponsor | Asan Medical Center |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Phase1/Phase2 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : Lenvatinib: 12 mg (for body weight = 60 kg) or 8 mg (for body weight < 60 kg) per oral once daily - Dose level 1: 8mg per oral once daily (for <60kg) 12mg per oral once daily (for = 60kg) - Dose level 2: 4mg per oral once daily (for… |
| Registration date | Aug 13, 2025 |
| Target size | 61 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: